Phase 1/2 Study of CORT125134 in Combination With With Nab-paclitaxel in Patients With Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs CORT 125134 (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Corcept Therapeutics
- 23 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.
- 23 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2019.
- 30 Jan 2017 According to Corcept Therapeutics media release, dose expansion portion of this trial is expected in fourth quarter of 2017.